Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Michael D. Kluger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4311-078X; OpenAlex author ID A5077950114. Sources: ClinicalTrials.gov.

Their work

Papers
40 (first author 0, last author 10)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
135
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 4 papers · 2024: 6 papers · 2025: 6 papers · 2026: 8 papers, 1 trial

Papers 40

  1. Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2026.0372↗
  2. Routine CT reporting of vascular involvement in pancreatic ductal adenocarcinoma: completeness and association with margin-positive resection. Co-author DOI 10.1007/s00261-026-05815-4↗
  3. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  4. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Last author DOI 10.1016/j.surg.2026.110302↗
  5. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  6. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Co-author DOI 10.1093/oncolo/oyag416↗
  7. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". Co-author DOI 10.1097/xcs.0000000000001738↗
  8. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353144↗
  9. Moving Beyond the Standard Pancreatectomy for Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.semradonc.2025.08.001↗
  10. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-025-02345-5↗
  11. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  12. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Co-author DOI 10.2214/ajr.24.32160↗
  13. The Impact of Social Determinants on Pancreatic Cancer Care in the United States. Co-author DOI 10.3390/cancers17121898↗
  14. The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254↗
  15. Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. Last author DOI 10.1002/jso.27851↗
  16. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… Co-author DOI 10.1016/j.hpb.2023.11.015↗
  17. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  18. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  19. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  20. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… Co-author DOI 10.3390/cancers16233894↗
  21. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Co-author DOI 10.1002/jhbp.1313↗
  22. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Co-author DOI 10.1007/s11605-023-05850-2↗
  23. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  24. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. Last author DOI 10.1093/bjs/znac393↗
  25. Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Last author DOI 10.1002/jso.27085↗
  26. Socioeconomic Predictors of Access to Care for Patients with Operatively Managed Pancreatic Cancer in New York State. Last author DOI 10.1007/s11605-022-05320-1↗
  27. Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Co-author DOI 10.1016/j.molcel.2022.06.005↗
  28. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2066767↗
  29. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Co-author DOI 10.3390/cancers14092067↗
  30. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  31. Irreversible electroporation of locally advanced pancreatic cancer. Last author DOI 10.1053/j.seminoncol.2021.02.004↗
  32. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elast… Co-author DOI 10.7150/thno.37965↗
  33. Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Last author DOI 10.1007/s11605-018-3936-1↗
  34. Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Co-author DOI 10.3390/cancers12010003↗
  35. Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist. Last author DOI 10.1007/s00261-017-1349-3↗
  36. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-017-3556-1↗
  37. Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma? Co-author DOI 10.1002/jmri.25581↗
  38. Imaging of pancreatic cancer: what the surgeon wants to know. Co-author DOI 10.1016/j.clinimag.2016.10.002↗
  39. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Co-author DOI 10.1245/s10434-015-5034-x↗
  40. Pancreatic cancer surgery and nutrition management: a review of the current literature. Last author DOI 10.3978/j.issn.2304-3881.2014.08.07↗

Trials 1

  1. Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations Principal investigator NCT07598357↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John A. Chabot · 17 shared papers, 2015–2026 · strength 2.24
  2. Alexander S. Thomas · 9 shared papers, 2021–2024 · strength 1.66
  3. Wooil Kwon · 9 shared papers, 2021–2024 · strength 1.66
  4. Beth Schrope · 11 shared papers, 2016–2026 · strength 1.59
  5. Greg D. Sacks · 6 shared papers, 2025–2026 · strength 1.55
  6. Christopher Lee Wolfgang · 5 shared papers, 2025–2026 · strength 1.27
  7. Gulam Abbas Manji · 6 shared papers, 2022–2026 · strength 1.06
  8. Joseph R. Habib · 4 shared papers, 2025–2026 · strength 0.98
  9. Ammar A. Javed · 4 shared papers, 2025–2026 · strength 0.98
  10. Kazuki N. Sugahara · 4 shared papers, 2022–2025 · strength 0.78
  11. Daniel Brock Hewitt · 3 shared papers, 2025–2026 · strength 0.75
  12. Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.74
  13. Sean Patrick Cleary · 3 shared papers, 2024–2026 · strength 0.74
  14. Carlos H.F. Chan · 3 shared papers, 2024–2026 · strength 0.74
  15. Rebekah Ruth White · 3 shared papers, 2024–2026 · strength 0.74
  16. Robert C.G. Martin · 3 shared papers, 2024–2026 · strength 0.74
  17. Mirang Lee · 4 shared papers, 2022–2024 · strength 0.73
  18. Won‐Gun Yun · 4 shared papers, 2022–2024 · strength 0.73
  19. Jin‐Young Jang · 4 shared papers, 2022–2024 · strength 0.73
  20. Camila Hidalgo Salinas · 3 shared papers, 2025–2026 · strength 0.71
  21. Susan Elaine Bates · 4 shared papers, 2022–2026 · strength 0.68
  22. Anirban Maitra · 4 shared papers, 2021–2026 · strength 0.64
  23. Elizabeth M. Hecht · 6 shared papers, 2016–2025 · strength 0.59
  24. Hye‐Sol Jung · 3 shared papers, 2023–2024 · strength 0.58
  25. Jeanine M. Genkinger · 4 shared papers, 2021–2024 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.